Alumis Inc ALMS
$28.25
▼ -2.42%
($-0.70)
🗓️ Earnings Next Week
Open
$28.95
Prev Close
$28.95
Day Range
$27.57 – $29.20
52W Range
$3.76 – $31.35
Market Cap
$3.60B
Beta
0.79
EPS (TTM)
$-1.93
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-06-28 |
| Shares Out. | 127,490,000 |
| Website | alumis.com/ ↗ |
| Phone | 16502316625 |
| Employees | 227 |
| Revenue | $1.7M |
| Gross Profit | $1.7M |
| Net Income | -$93.1M |
| Free Cash Flow | -$377.0M |
| Total Assets | $671.6M |
| Total Liabilities | $104.6M |
| Equity | $567.0M |
About Alumis Inc
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
Alumis Inc is a publicly traded company under the ticker symbol ALMS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)